Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A WERNER

Showing results (1181-1190 of 1,356) with videos related to

Pageof 136
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 2018
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell LymphomaConstantin Lapa, Heribert Hänscheid, Malte Kircher, et al.
Annals of Nuclear Medicine|November 11, 2020
<sup>18</sup>F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphomaThorsten Derlin, Christian Schultze-Florey, Rudolf A Werner, et al.
Rapid Communications in Mass Spectrometry : RCM|September 9, 2016
Reassessment of the NH<sub>4</sub> NO<sub>3</sub> thermal decomposition technique for calibration of the N<sub>2</sub> O isotopic compositionJoachim Mohn, Wilhelm Gutjahr, Sakae Toyoda, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2022
Matched-pair analysis of [<sup>177</sup>Lu]Lu-PSMA I&T and [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancerPhilipp E Hartrampf, Franz-Xaver Weinzierl, Andreas K Buck, et al.
British Journal of Cancer|November 16, 2002
A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/epinephrine gelJ A Werner, W Kehrl, A Pluzanska, et al.
Diagnostic and Interventional Imaging|August 2, 2025
Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor typesJorge D Oldan, Anurag Anugu, Md Zobaer Islam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 20, 2023
Early biochemical and radiographic response after one cycle of [<sup>177</sup>Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patientsWojciech Cytawa, Robin Hendel, Bartłomiej Tomasik, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2023
Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand TherapyPhilipp E Hartrampf, Patrick W Mihatsch, Anna Katharina Seitz, et al.
Cancers|May 14, 2025
Detection of Local Prostate Cancer Recurrence from PET/CT Scans Using Deep LearningMarko Korb, Hülya Efetürk, Tim Jedamzik, et al.
Cancers|January 21, 2023
Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors-A Pan-Cancer Machine Learning Workflow for Theranostic Target StructuresAndré Marquardt, Philipp Hartrampf, Philip Kollmannsberger, et al.
Pageof 136

Showing results (1181-1190 of 1,356) with videos related to

Sort By:
Pageof 136
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 2018
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell LymphomaConstantin Lapa, Heribert Hänscheid, Malte Kircher, et al.
Annals of Nuclear Medicine|November 11, 2020
<sup>18</sup>F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphomaThorsten Derlin, Christian Schultze-Florey, Rudolf A Werner, et al.
Rapid Communications in Mass Spectrometry : RCM|September 9, 2016
Reassessment of the NH<sub>4</sub> NO<sub>3</sub> thermal decomposition technique for calibration of the N<sub>2</sub> O isotopic compositionJoachim Mohn, Wilhelm Gutjahr, Sakae Toyoda, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2022
Matched-pair analysis of [<sup>177</sup>Lu]Lu-PSMA I&T and [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancerPhilipp E Hartrampf, Franz-Xaver Weinzierl, Andreas K Buck, et al.
British Journal of Cancer|November 16, 2002
A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/epinephrine gelJ A Werner, W Kehrl, A Pluzanska, et al.
Diagnostic and Interventional Imaging|August 2, 2025
Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor typesJorge D Oldan, Anurag Anugu, Md Zobaer Islam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 20, 2023
Early biochemical and radiographic response after one cycle of [<sup>177</sup>Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patientsWojciech Cytawa, Robin Hendel, Bartłomiej Tomasik, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2023
Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand TherapyPhilipp E Hartrampf, Patrick W Mihatsch, Anna Katharina Seitz, et al.
Cancers|May 14, 2025
Detection of Local Prostate Cancer Recurrence from PET/CT Scans Using Deep LearningMarko Korb, Hülya Efetürk, Tim Jedamzik, et al.
Cancers|January 21, 2023
Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors-A Pan-Cancer Machine Learning Workflow for Theranostic Target StructuresAndré Marquardt, Philipp Hartrampf, Philip Kollmannsberger, et al.
Pageof 136